Olympus Bilan de santé

Santé financière contrôle des critères 6/6

Olympus possède un total de capitaux propres de ¥790.1B et une dette totale de ¥254.6B, ce qui porte son ratio d'endettement à 32.2%. Son actif total et son passif total sont ¥1,515.4B et de ¥725.3B. L'EBIT de Olympus est ¥120.6B ce qui fait que son ratio de couverture des intérêts 19.5. Elle dispose de liquidités et de placements à court terme de ¥274.4B.

Informations clés

32.2%

Ratio d'endettement

JP¥254.55b

Dette

Ratio de couverture des intérêts	19.5x
Argent liquide	JP¥274.41b
Fonds propres	JP¥790.06b
Total du passif	JP¥725.33b
Total des actifs	JP¥1.52t

Mises à jour récentes de la santé financière

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Jul 14

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 7733 ( ¥736.6B ) dépassent ses passifs à court terme ( ¥419.2B ).

Passif à long terme: Les actifs à court terme de 7733 ( ¥736.6B ) dépassent ses passifs à long terme ( ¥306.1B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 7733 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 7733 a été réduit de 42.1% à 32.2% au cours des 5 dernières années.

Couverture de la dette: La dette de 7733 est bien couverte par le flux de trésorerie opérationnel ( 46.6% ).

Couverture des intérêts: Les paiements d'intérêts de 7733 sur sa dette sont bien couverts par l'EBIT ( 19.5 x couverture).

Olympus Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Recent updates

Olympus Corporation Announces Resignation of Stefan Kaufmann as Chief Executive Officer, Effective October 28, 2024

Olympus (TSE:7733) Hasn't Managed To Accelerate Its Returns

A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Announces Executive Changes, Effective October 1, 2024

High number of new directors

Does Olympus (TSE:7733) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Estimating The Fair Value Of Olympus Corporation (TSE:7733)

High number of new directors

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Slowing Rates Of Return At Olympus (TSE:7733) Leave Little Room For Excitement

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Upcoming dividend of JP¥18.00 per share

Olympus Corporation's (TSE:7733) Share Price Matching Investor Opinion

Dividend of JP¥18.00 announced

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

New minor risk - Earnings quality

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Now 21% overvalued after recent price rise

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Full year 2023 earnings: EPS misses analyst expectations

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 38%

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Now 21% undervalued after recent price drop

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Now 21% undervalued

Consensus EPS estimates increase by 79%

Consensus EPS estimates fall by 61%

Upcoming dividend of JP¥16.00 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: JP¥28.43 (vs JP¥19.66 in 3Q 2022)

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2023 earnings released

Second quarter 2023 earnings released

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Full year 2022 earnings: Revenues in line with analyst expectations

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Investor sentiment improved over the past week

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Olympus Corporation Announces Dividend for the Year Ended March 31, 2022, Payable on June 3, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

High number of new directors

Olympus Corporation to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥14.00 per share

Now 21% undervalued after recent price drop

Olympus Announces FDA Clearance of the Celeris Single-Use Sinus Debrider

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Analyse de la situation financière